肝素-泊洛沙姆水凝胶脑内递送rhFGF20促进缺血性卒中神经恢复
该研究在大鼠脑缺血再灌注模型及体外氧糖剥夺-复氧模型中,于卒中后第5天经肝素-泊洛沙姆水凝胶脑内植入给予rhFGF20(1 mg/mL,20 μL),发现其可减轻神经行为缺陷和梗死体积,并促进神经发生与血管新生。
要点
- 肝素-泊洛沙姆水凝胶可提高rhFGF20稳定性和生物利用度。
- 卒中后第5天脑内植入HP-rhFGF20改善大鼠神经行为缺陷和梗死体积。
- HP-rhFGF20促进神经干细胞增殖、迁移、分化及血管新生。
核心结论
- HP-rhFGF20通过增强神经发生和血管新生促进缺血性卒中大鼠功能恢复。
研究设计与样本
- 建立大鼠大脑中动脉闭塞/再灌注模型和氧糖剥夺-复氧细胞模型模拟缺血性卒中。
- 卒中后第5天经肝素-泊洛沙姆水凝胶植入脑内给予rhFGF20(1 mg/mL,20 μL)。
- 检测卒中患者血清、缺血大鼠皮质及氧糖剥夺-复氧损伤神经元中内源性FGF20水平。
主要发现
- 缺血性卒中患者血清、缺血大鼠皮质及氧糖剥夺-复氧损伤神经元中检测到FGF20高表达。
- HP-rhFGF20减轻缺血性卒中大鼠神经行为缺陷和梗死体积。
- 植入后第7天HP-rhFGF20抑制神经元细胞死亡、小胶质细胞激活和胶质瘢痕形成。
- HP-rhFGF20促进神经干细胞增殖、迁移、分化并改善神经元可塑性和血管新生。
关键数值与推荐
- 肝素-泊洛沙姆提高rhFGF20的稳定性和生物利用度。
- 采用TTC染色、mNSS、转角试验、转棒试验、圆筒试验和Morris水迷宫评估神经恢复。
临床怎么用
- 提示生长因子联合生物材料脑内递送可能成为中枢神经系统疾病治疗策略。
- 卒中后延迟经水凝胶脑内给予rhFGF20可能促进神经修复。
局限性
- 研究基于大鼠模型和体外细胞模型,尚无人体临床疗效数据。
- 脑内植入给药方式的有创性及长期安全性未在摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic stroke poses a significant threat to human health. FGF (fibroblast growth factor) 20 is involved in the repair of central nervous system diseases, but it has the shortcomings of short half-life and inability to penetrate the blood-brain barrier. Therefore, to overcome the drawbacks of rhFGF20 (recombinant human FGF20) and explore its role in ischemic stroke, the effects of intracerebral administration of rhFGF20 by heparin-poloxamer hydrogel (HP-rhFGF20 [heparin-poloxamer hydrogel-encapsulated rhFGF20]) in a rat stroke model were the focus of this study. METHODS: A rat model of middle cerebral artery occlusion/reperfusion and oxygen-glucose deprivation-reoxygenation models were established to mimic ischemic stroke in vivo and in vitro, respectively. Endogenous FGF20 levels were measured in patients, ischemic rats, and oxygen-glucose deprivation-reoxygenation-injured neurons. To assess the therapeutic potential, rhFGF20 was administered intracerebrally via heparin-poloxamer hydrogel implants (1 mg/mL, 20 μL) on day 5 poststroke. 2,3,5-Triphenyltetrazolium chloride staining, neurobehavioral tests (including the mNSS test [modified Neuro-Severity Score], the corner test, the rotarod test, the cylinder test, and the Morris water maze test), and Nissl staining were performed to evaluate neurological recovery. Immunofluorescence and Western blotting were conducted to assess the brain repair processes (neurogenesis, neuronal remodeling, and angiogenesis). RESULTS: High expression of FGF20 was detected in the serum of patients with ischemic stroke, the cortex of ischemic rats, and oxygen-glucose deprivation-reoxygenation-injured neurons. Heparin-poloxamer increased the stability and bioavailability of rhFGF20. HP-rhFGF20 attenuated neurobehavioral deficits and infarct volume in ischemic stroke rats. HP-rhFGF20 inhibited neuronal cell death, microglial activation, and glial scar formation on day 7 post-implantation. Moreover, HP-rhFGF20 promoted the proliferation, migration, and differentiation of neural stem cells and improved neuronal plasticity and angiogenesis in ischemic stroke rats. CONCLUSIONS: HP-rhFGF20 promoted functional recovery in ischemic stroke rats by enhancing neurogenesis and angiogenesis. The combination of growth factors and biomaterials provides a promising therapeutic strategy for central nervous system diseases. REGISTRATION: URL: http://www.chictr.org.cn; Unique identifier: ChiCTR2100051104.
引用
- Ye S, Zhao Y, Xu Y, et al. Intracerebral Delivery of rhFGF20 via Heparin-Poloxamer Hydrogel Promotes Neurological Recovery in Ischemic Stroke. Stroke. 2025. PMID: 40495806. doi:10.1161/STROKEAHA.125.050828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。